drugset / Trial / NCT04125745
Oral CXA-10 in Pulmonary Arterial Hypertension
Phase 2
Terminated
1 enrolled
Gladwin, Mark, MD
Complexa, Inc. · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on changes in hemodynamics, exercise capacity, cardiovascular function and patient reported outcomes.
Timeline
- Start
- 2019-10-31
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CXA-10 | Small molecule | 300 mg | Oral |